The aberrant functionality of CD8+ T cells has been observed in patients with myeloid neoplasms compared with healthy individuals (4, 8, 9), rendering this cell population a major target for immunotherapeutic interventions (10, 11). Here, CD8A is linked to myeloid neoplasm.